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Abstract
Background: Alterations in carbohydrate metabolism are frequently observed in cirrhosis. We
conducted this study to define the prevalence of diabetes mellitus (DM) and impaired glucose
tolerance (IGT) in Iranian patients with chronic liver disease (CLD), and explore the factors
associated with DM in these patients.
Methods: One hundred and eighty-five patients with CLD were enrolled into the study. Fasting
plasma glucose and two-hour plasma glucose were measured in patients' sera. DM and IGT were
diagnosed according to the latest American Diabetes Association criteria.
Results: The subjects included 42 inactive HBV carriers with a mean age of 42.2 ± 12.0 years, 102
patients with HBV or HCV chronic hepatitis with a mean age of 41.2 ± 10.9 years, and 41 cirrhotic
patients with a mean age of 52.1 ± 11.4 years. DM and IGT were diagnosed in 40 (21.6%) and 21
(11.4%) patients, respectively. Univariate analysis showed that age (P = 0.000), CLD status (P =
0.000), history of hypertension (P = 0.007), family history of DM (P = 0.000), and body mass index
(BMI) (P = 0.009) were associated with DM. Using Multivariate analysis, age (OR = 4.7, 95%CI: 1.8–
12.2), family history of DM (OR = 6.6, 95%CI: 2.6–17.6), chronic hepatitis (OR = 11.6, 95%CI: 2.9–
45.4), and cirrhosis (OR = 6.5, 95%CI: 2.4–17.4) remained as the factors independently associated
with DM. When patients with cirrhosis and chronic hepatitis were analyzed separately, higher
Child-Pugh's score in cirrhotic patients (OR = 9.6, 95%CI: 1.0–88.4) and older age (OR = 7.2,
95%CI: 1.0–49.1), higher fibrosis score (OR = 59.5, 95%CI: 2.9–1211.3/ OR = 11.9, 95%CI: 1.0–
132.2), and higher BMI (OR = 30.3, 95%CI: 3.0–306.7) in patients with chronic hepatitis were found
to be associated with higher prevalence of DM.
Conclusions: Our findings indicate that patients with cirrhosis and chronic hepatitis are at the
increased risk of DM occurrence. Older age, severe liver disease, and obesity were associated with
DM in these patients.
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Alterations in carbohydrate metabolism are frequently
observed in liver cirrhosis. Glucose metabolism impair-
ment in cirrhotic patients, both in fasting state and in
response to oral glucose or meals has been widely docu-
mented in the literature [1-5]. There is a wide variability
in the prevalence of overt diabetes mellitus (DM) and
impaired glucose tolerance (IGT) according to various
reports. In fact, the laboratory methods and the criteria
used to state glucose metabolism status are different
among various studies, considering the fact that the crite-
ria for diagnosing DM and IGT have been modified a cou-
ple of times during last decade. On the other hand, the
majority of the papers focused on cirrhosis [2,3,6-10]
although a number of studies evaluated patients with
chronic hepatitis, as well [4,5,11,12]. Furthermore, in
many studies investigating the correlation between liver
disease and glucose tolerance, a number of potent factors
for DM such as BMI have been overlooked.
In this study, for the first time in Iran, we reported the
prevalence of DM and IGT in patients with chronic liver
disease (CLD) using the latest generally accepted criteria,
and investigated independent correlation of CLD with
DM, considering other known possible DM risk factors.
Moreover, we explored the factors that might be poten-
tially associated with DM in patients with cirrhosis and
chronic hepatitis.
Methods
From October 2002 to March 2003, all consecutive
patients with chronic liver disease referred to "Tehran
Hepatitis Center" were enrolled into the study. Tehran
Hepatitis Center is a referral specialized clinic for liver dis-
eases where many patients suffering from liver diseases
and hepatitis from around Iran are referred to in order to
receive consultation and clinical medical care. Pregnant
females, patients under 20 years old, those who were on
regular corticosteroid or hydrochlorothiazide therapy,
known or suspected cases of hemochromatosis, or
autoimmune disease were excluded. Having a clinical,
biochemical (serum amylase and/or lipase elevation) or
ultrasonographic evidence for chronic pancreatitis was
also considered an exclusion criterion. No patient had a
history of habitual drinking. All of the patients were Mos-
lem and belonged to the white race.
A total number of 193 patients who met the criteria were
eligible to enter the study. First group included 41 cir-
rhotic patients. Mean age was 52.1 ± 11.4 years ranging
between 26–74 years. Diagnosis of cirrhosis was con-
firmed by histology in 17 (41.5%) patients. The occur-
rence of signs or biochemical evidences of liver
decompensation, ultrasound features of portal hyperten-
sion and/or esophageal varices in gastroscopy were used
for the clinical diagnosis in the remaining cases. No cir-
rhotic patients had evidence of hepatocellular carcinoma,
screened by serum alpha-fetoprotein level test and
abdominal ultrasonography. Severity of liver cirrhosis was
graded according to Child-Pugh's classification. Second
group included 102 patients with chronic hepatitis B, or
C. Mean age was 41.2 ± 10.9 years ranging between 22–67
years. All patients had adequate documentation of ele-
vated serum aminotransferases for more than 6 months,
and viral hepatitis molecular assays by qualitative RT-
PCR. In 91 (89.2%) patients liver biopsy reports were
accessible. The histological staging and grading in liver
biopsy was scored according to Knodell scoring. Third
group included 42 inactive hepatitis B virus (HBV) carriers
who were hepatitis B s antigen (HBsAg) positive, quanti-
tative HBV DNA level less than 105 copies/ml (ROCHE
Cobas Amplicore) and normal liver enzymes. The mean
age in this group was 42.2 ± 12.0 years ranging between
23–84 years. Eight patients with nonalcoholic steatohep-
atitis (NASH) were initially enrolled but were not entered
in analysis because of the low case number. Therefore
analysis was finally performed for 185 patients.
Informed consent in writing was obtained from each
patient involved and the study protocol conformed to the
ethical guidelines of the 1975 Declaration of Helsinki as
approved by institutional review board. Initial data were
collected by chart review and interview. Then, two venous
blood samples were taken: First sample in the morning
after a 12-hour overnight fast to measure fasting plasma
glucose (FPG) level, triglycerides (TG) level, and choles-
terol (Chol) level; and a second sample following 2 hours
after eating 75 gr glucose to measure two-hour post-
loaded glucose (2-hr PG). FPG and 2-hr PG measurement
were repeated on two other samples in second session.
Patients receiving therapy with insulin or oral hypoglyc-
emic medications were considered as diabetics. In other
patients, FPG ≥ 126 mg/dl or 2-hr PG ≥ 200 mg/dl on
more than one occasion was used as diagnostic for DM in
agreement with the latest American Diabetes Association
(ADA) criteria [13]. FPG between 110 mg/dl and 126 mg/
dl was considered as impaired fasting glucose (IFG), and
2-hr PG between 140 mg/dl and 200 mg/dl was consid-
ered as IGT according to ADA definitions [13].
Body mass index (BMI) was calculated using the standard
formula of weight in kilogram divided by square of height
in meters (kg/m2).
Results were expressed as mean ± standard deviation
(SD). Comparison between diabetic and non-diabetic
groups was made using Students T test for continuous var-
iables and the Chi-square or Fisher exact test for categori-
cal variables. At univariate analysis the factors possiblyPage 2 of 7
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tivariate analysis based on a stepwise logistic regression
model was used to assess the independent effect of all var-
iables found significant at the univariate analysis. P-value
less than 0.05 was considered significant. All statistical
analyses were performed using SPSS for Windows soft-
ware (version 10.0; SPSS Inc. Chicago, Illinois, USA).
Results
The sample population contained 150 (81.1%) males and
35 (18.9%) females. The overall mean age was 43.8 ± 12.0
years ranging between 22 and 84 years. In the total of 185
patients, DM was found in 40 (21.6%) patients, and IFG
and/or IGT was found in 21 (11.3%) patients. Thirty
patients were already aware of their problem whereas the
diagnosis of DM was new in 10 patients.
By univariate analysis a number of variables including the
factors mentioned by ADA as risk factors for type II diabe-
tes [13] in addition to status and etiology of liver disease,
interferon therapy, and history of or ongoing habitual
smoking were compared between diabetic and non-dia-
betic patients (Table 1). We found that the prevalence of
DM was significantly associated with older age (P =
0.000), CLD status (P = 0.000), history of hypertension (P
= 0.007), family history of DM (P = 0.000), and higher
BMI (0.009). Excluding the inactive carriers, we compared
DM rate in two other groups. The prevalence of DM
among cirrhotic cases (53.7%) was significantly higher
than that of chronic hepatitis patients (13.7%), (P =
0.000).
At multivariate analysis age (P = 0.008, OR = 4.7, 95%CI:
1.8–12.2), family history of DM (P = 0.000, OR = 6.6,
95%CI: 2.6–17.6), chronic hepatitis (0.000, OR = 11.6,
95%CI: 2.9–45.4), and cirrhosis (P = 0.000, OR = 6.5,
95%CI: 2.4–17.4) showed up as the only factors inde-
pendently associated with DM prevalence rate (table 2).
Since both cirrhosis and chronic hepatitis were found as
independent factors associated with DM occurrence, we
analyzed these two groups separately. The results were
summarized in table 3.
Out of 41 cirrhotic patients, 22 (53.7%) patients were dia-
betic and 7 (17.1%) patients had IFG and/or IGT. Univar-
iate analysis showed that only two factors were associated
with DM rate. Mean of age in diabetic cases was signifi-
cantly higher than that of non-diabetic ones (P = 0.003).
Moreover, DM was significantly more prevalent in
patients with Child-Pugh's score B than score A (P = 0.04).
Since there was no score C in study sample, we could not
evaluate this class of cirrhosis. After applying logistic
model, only Child-Pugh's score kept its significance (P =
Table 1: Clinical and epidemiological characteristics of CLD 




Female 9 (22.5%) 26 (17.9%)
Male 31 (77.5%) 119 (82.1%)
Age 50.3 ± 11.4 40.2 ± 10.6 0.000
CLD status 0.000
Inactive carrier 4 (10.0%) 38 (26.2%)
Chronic hepatitis 14 (35.0%) 88 (60.7%)
Cirrhosis 22 (55.0%) 19 (13.1%)
CLD etiology NS
HBV 24 (60.0%) 85 (58.6%)
HCV 13 (32.5%) 58 (40.0%)
Cryptogenic 3 (7.5%) 2 (1.4%)
Family history of DM* 0.000
Yes 21 (52.5%) 29 (20.0%)
No 19 (47.5%) 116 (80%)
History of hypertension† 0.007
Yes 10 (25.0%) 13 (9.0%)
No 30 (75.0%) 132 (91.0%)
BMI 27.5 ± 4.6 24.7 ± 4.0 0.009
Interferon therapy NS
Yes 6 (15.0%) 49 (33.8%)
No 34 (85.0%) 96 (66.2%)
Smoking NS
Yes 13 (32.5%) 37 (25.5%)
No 27 (67.5%) 108 (74.5%)
TG 179.2 ± 74.1 142.8 ± 71.4 NS
Chol 192.4 ± 39.8 174.7 ± 44.4 NS
*Indicates presence of at least one first-degree relative affected by 
DM.
†Includes patients who require diet or antihypertensive agents.
Table 2: Logistic regression analysis of factors associated with 
DM among patients with CLD
OR 95% CI P-value
Age
< 45 years 1.0
≥ 45 years 4.7 1.8 – 12.2 0.001
CLD status
Inactive carrier 1.0
Chronic hepatitis 11.6 2.9 – 45.4 0.000
Cirrhosis 6.5 2.4 – 17.4 0.000
Family history of diabetes
No 1.0
Yes 6.6 2.6 – 16.7 0.000
History of hypertension
No 1.0
Yes 2.3 0.7 – 8.1 NS
BMI
> 25 1.0
≥ 25 1.4 0.5 – 3.4 NSPage 3 of 7
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dictive factor for DM in cirrhotic patients (table 4).
In chronic hepatitis group including 102 patients, DM
was found in 14 (13.7%) patients and IFG and/or IGT was
found in 11 (10.8%) patients. There was no significant
difference between diabetic and non-diabetic cases in
regard with sex, etiology of chronic hepatitis, hyperten-
sion, interferon therapy, smoking, and serum TG and
Chol levels. On the other hand, diabetic patients had
higher mean age compared with non-diabetic cases (P =
0.001). More cases of diabetic patients compared with
non-diabetic ones had a family history of DM (P = 0.01).
The mean BMI of patients with DM was higher than that
of patients without DM (P = 0.02). Furthermore, liver
biopsy showed significantly more fibrosis activity in dia-
betic patients compared with non-diabetic cases (P =
0.003), whereas no difference in diabetic vs. non-diabetic
patients was seen with respect to histological grading.
Multivariate analysis revealed that older age (P = 0.04, OR
= 7.2, 95%CI: 1.0–49.1), higher BMI (P = 0.004, OR =
30.3, 95%CI: 3.0–306.7), and more severe fibrosis activity
(stage 2–3: P = 008, OR = 59.5, 95%CI: 2.9–1211.3; stage
4–6: P = 0.04, OR = 11.9, 95%CI: 1.0–132.2) were the pre-
dictive variables for DM in patients with chronic hepatitis
(table 4).
Table 3: Clinical and epidemiological characteristics of patients with and without DM separated to cirrhosis and chronic hepatitis 
groups
Patients with cirrhosis Patients with chronic hepatitis
Diabetic Non-diabetic P-value Diabetic Non-diabetic P-value
Number 22 19 14 88
Sex NS NS
Female 4 (18.2%) 3 (15.8%) 2 (14.3%) 12 (13.6%)
Male 18 (81.8%) 16 (84.2%) 12 (85.7%) 76 (86.4%)
Age 56.9 ± 10.6 46.6 ± 10.0 0.003 49.7 ± 7.8 39.9 ± 10.7 0.001
CLD etiology NS NS
HBV 11 (50.0%) 13 (68.4%) 10 (71.4%) 37 (42.0%)
HCV 8 (36.4%) 4 (21.1%) 4 (28.6%) 51 (58.0%)
Criptogenic 3 (13.6%) 2 (10.5%) - -
Family history of DM NS 0.01
Yes 9 (40.9%) 3 (15.8%) 8 (57.1%) 21 (23.9%)
No 13 (59.1%) 16 (84.2%) 6 (42.9%) 67 (76.1%)
History of hypertension NS NS
Yes 6 (27.3%) 1 (5.3%) 3 (21.4%) 8 (9.1%)
No 16 (72.7%) 18 (94.7%) 11 (78.6%) 80 (90.9%)
BMI 26.4 ± 3.4 26.4 ± 4.0 NS 27.7 ± 4.8 24.5 ± 3.1 0.02
Interferon therapy NS NS
Yes 2 (9.1%) 3 (15.8%) 4 (28.6%) 46 (52.3%)
No 20 (90.9%) 16 (84.2%) 10 (71.4%) 42 (47.7%)
Smoking NS NS
Yes 5 (22.7%) 5 (26.3%) 7 (50.0%) 25 (28.4%)
No 17 (77.3%) 14 (73.7%) 7 (50.0%) 63 (71.6%)
TG 145.5 ± 58.6 109.3 ± 75.2 NS 174.9 ± 82.5 140.6 ± 53.8 NS
Chol 141.6 ± 50.5 151.8± 32.5 NS 199.8 ± 42.8 163.9 ± 36.1 NS
Child-Pugh's score 0.04
Score A 13 (65.0%) 18 (94.7%) - - -
Score B 7 (35.0%) 1 (5.3%)
Histological staging* 0.003
0–1 - - - 1 (8.3%) 33 (41.8%)
2–3 3 (25.0%) 30 (38.0%)
4–6 8 (66.7%) 16 (20.3%)
Histological grading* NS
0–4 - - - 2 (16.7%) 36 (45.6%)
5–8 8 (66.7%) 34 (43.0%)
≥ 9 2 (16.7%) 9 (11.4%)
* According to Knodell scorePage 4 of 7
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There is a wide range in the prevalence of glucose metab-
olism alterations in cirrhotic patients in various studies.
The frequency for overt DM has been reported from 10%
to 50% and for IGT up to more than 70% [1-5,7,8,10,11].
Such variations may be mainly due to the criteria
employed in the diagnosis of DM. In our study, we
employed latest ADA criteria and DM was presented in
21.6% of patients with CLD (53.7% in cirrhosis, 13.7% in
chronic hepatitis, and 9.5% in HBV inactive carrier). In
Iran the estimated prevalence of overt DM in general pop-
ulation is in the range of about 7.5–10 percent [14-16],
which is about 2 to 3 times less than what we found in this
study, indicating that patients with CLD are a high-risk
population for DM. In spite of this fact, we showed that 10
out of 40 (25%) diabetic cases found in this study were
unaware of their endocrinal problem before being
screened as part of this study. This finding highlights the
importance of periodical screening of the patients with
CLD especially in advanced stages.
Literature frequently demonstrated the higher prevalence
of DM and IGT in cirrhosis than in chronic hepatitis
[4,5,11]. However, about the higher DM rate in patients
with chronic hepatitis compared with people without
liver disease, there is not any widely general agreement.
Some studies claimed that DM rate is not appreciably dif-
ferent when compared with general population or indi-
viduals without liver disease [11,17]. These studies
believed that only cirrhosis but not chronic hepatitis were
associated with DM [17]. In our study, multivariate anal-
ysis indicates independent association between chronic
hepatitis and DM rate, despite the fact that we compared
DM occurrence among three groups who all suffered from
liver disease. Moreover, our data indicate that the fre-
quency of DM increases significantly with the severity of
the liver disease both in cirrhotic cases and in patients
with chronic hepatitis. These findings suggest that liver
fibrosis but not cirrhosis itself, is the event associated with
glucose intolerance. A weak association between glucose
intolerance and severity of liver disease in cirrhosis has
already been reported by Muller et al [7], even though
they used different criteria to evaluate liver damage sever-
ity. Another study applying Child-Pugh's classification
showed similar results [11]. In this context it is worthy to
note that although the underlying mechanism of glucose
intolerance in cirrhosis has not been fully elucidated, it
can be mainly explained by the insulin resistance [9], in
addition to reduced glucose sensitivity in liver cirrhosis
[18,19]. More interestingly, a recent study suggests that
insulin resistance occurs already in the early stages of the
chronic hepatitis course [12], and another study investi-
gating chronic hepatitis patients with normal glucose tol-
erance revealed a strong relationship between insulin
sensitivity and fibrosis score [20]. In contrast, there is
another hypothesis that indicates CLD as a consequence
of DM. This theory states that occurrence of insulin resist-
ance initially facilitates lipolysis, and increases free fatty
acid deposition in liver, which increases products of lipid
peroxidation inducing oxidative stress. This results in
cytokine-mediated hepatic inflammatory damage that
induces collagen deposition and eventually fibrosis
[21,22]. Although in this study we could not determine if
the onset of DM was before or after of liver disease, our
findings show that chronic hepatitis per se has an inde-
pendent association with DM, and development of DM in
chronic hepatitis patients was correlated to the severity of
liver fibrosis.
No differences in DM rate were found when we studied
patients according to CLD etiological categories both in
cirrhosis and in chronic hepatitis group. A positive link
between hepatitis C infection and development of DM
has been suggested in some studies but not completely
characterized. Mason et al surveying a large cohort of
patients with viral chronic hepatitis showed a relatively
strong association between DM and HCV infection [23].
They suggested that HCV infection may serve as an addi-
tional risk factor for the development of DM beyond that
attributable to CLD alone [23]. In contrast, some studies
provided evidence against a potential association between
these two disorders [17,24]. A more recent study showed
that the prevalence of DM among cirrhotic patients with
Table 4: Logistic regression analysis of factors associated with 
DM among cirrhotic patients and patients with chronic 
hepatitis.
OR 95% CI P-value
Cirrhosis
Age
< 45 years 1.0
≥ 45 years 2.1 0.4 – 10.5 NS
Child Pugh's Score
Score A 1.0
Score B 9.6 1.0 – 88.4 0.04
Chronic hepatitis
Age
> 45 years 1.0
≥ 45 years 7.2 1.0 – 49.1 0.04
Family history of diabetes
No 1.0
Yes 2.0 0.3 – 13.9 NS
BMI
> 25 1.0
≥ 25 30.3 3.0 – 306.7 0.004
Histological staging
0–1 1.0
2–3 59.5 2.9 – 1211.3 0.008
4–6 11.9 1.0 – 132.2 0.04Page 5 of 7
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with cirrhosis due to cholestatic liver disease, but this rate
difference was not significant when compared with cases
with alcohol-induced cirrhosis [10]. In spite of the fact
that they had not enrolled HBV infected cases in their
sample population, it suggested that the mechanism of
the DM in cirrhotic patients was related more closely to
the underlying cause of liver cirrhosis [10]. Although no
single etiological factor was found linked to DM occur-
rence in our study, we believe that our study was not
designed to address this issue considering the fact that we
had to exclude patients with NASH as another etiology of
CLD because of small number of patients in this group.
However, further prospective studies may shed more light
on the relationship between DM and the underlying liver
disease.
BMI did not differ between diabetic and non-diabetic
cases among cirrhotic patients. This finding was
expectable as reduction in the muscle mass is well
described in liver cirrhosis, which can bias the compari-
son. On the other hand, among patients with chronic hep-
atitis BMI did remain as an independent predictive factor
of DM. Some studies have indicated that obesity could be
a potential risk factor for fibrosis in chronic hepatitis [25].
Our results suggest that increased BMI also has a role in
the pathogenesis of DM in chronic hepatitis independent
of liver fibrosis. Furthermore, Muller et al reported that
basal free fatty acids and basal free glycerol plasma con-
centrations were increased in diabetic patients with liver
cirrhosis when compared with those without diabetes [7].
In present study, TG and Chol levels in patients with
chronic hepatitis and TG level in cirrhotic patients were
higher in diabetic cases compared with non-diabetic ones
although not statistically significant (table 3). These find-
ings may have therapeutic implications in the manage-
ment of patients with chronic hepatitis. It appears
necessary to greatly encourage overweight patients to
make a concerted effort to lose weight in order to both
decrease the risk of DM development and to prevent the
liver damage.
Although family history of DM is a well-known risk factor
for DM, the correlation between DM and both cirrhosis
and chronic hepatitis remained significant even when
family history of DM was entered through logistic model.
This finding, in concordance with similar studies [7,11],
indicates that liver injury per se is associated with DM and
a family history of DM is only an adjunctive factor. How-
ever, the possible reporting bias of family history of DM
should be carefully considered as it is not unreasonable to
think that patients with known DM may be more likely to
know or think that they have a family history of DM.
When cirrhosis and chronic hepatitis groups were ana-
lyzed separately, we observed that patients with a positive
family history of DM did not show an increased frequency
of DM, particularly in cirrhotic patients. Slightly less than
45% of cirrhotic cases with a negative family history of
DM were diabetic. This finding does not support the spec-
ulation that cirrhotic patients only with a genetic predis-
position for DM are prone to glucose intolerance as the
manifestation of their liver disease.
Age is another definite risk factor for type II DM in the
normal population [13], and it was expected also to be
associated with DM in CLD. However, the odds ratio for
both cirrhosis and chronic hepatitis was higher than that
for age, implying a stronger association of the former fac-
tors. Although in the part of our study investigating cir-
rhotic patients, age lost its significance when it was
entered in multivariate analysis, the majority of studies
demonstrated that IGT and also DM were more frequently
seen at advanced age in cirrhotic patients [2,7,11].
While DM was associated with hypertension in univariate
analysis (table 1), in multivariate analysis it lost its signif-
icance as a predictor of DM (table 2). These two variables
may both be related to the metabolic syndrome and
adjustment for other related variables removes this associ-
ation. On the other hand, it is currently believed that car-
diovascular disease is rare in cirrhosis and studies
demonstrate that cirrhotic patients, even in the presence
of overt DM, have a low prevalence of vascular disease
including hypertension [26]. Our findings support this
hypothesis showing no difference in the rate of hyperten-
sion between diabetic and non-diabetic patients.
A few patients have so far been reported to develop DM
during interferon therapy [27], but the evidences are
insufficient in this regard as yet. In our study, interferon
therapy had no impact on the prevalence of DM, since
15% of subjects with DM and about 39% without had a
recorded use of interferon, and the difference was not sig-
nificant. This is in line with some previous studies clarify-
ing the impact of long-term administration of interferon
on glucose metabolism [28].
Conclusions
In summery, the present study indicates a high prevalence
of DM in patients with CLD in Iran although the relatively
small number of patients in each of the three subgroups
particularly cirrhosis and inactive carriers was a major
shortcoming of our study and may have potentially
underestimated or overestimated the prevalence of DM in
these subgroups of patients. Since a considerable number
of diabetic patients were unaware of their problem, it is
imperative that the patients be screened for glucose intol-
erance periodically. For more severe stages of liver disease
the screening interval appears to be shorter because of
higher probability for DM occurrence. Furthermore, ourPage 6 of 7
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patients with chronic hepatitis is of benefit in order to pre-
vent the occurrence of DM.
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